Natriumoxybat Aristo (Sodium Oxybate)

Sodium Oxybate, the active ingredient in Natriumoxybat Aristo, is a Gamma-hydroxybutyrate (GHB) derivative presented as an unknown/unknown for oral use. It treats narcolepsy with cataplexy in patients who require reduction of cataplexy episodes and improvement of daytime alertness.

GNH USA supplies Natriumoxybat Aristo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Natriumoxybat Aristo is a Gamma-hydroxybutyrate derivative indicated for disorders of excessive daytime sleepiness and cataplexy.

- Narcolepsy with cataplexy: reduces the frequency and severity of cataplexy attacks while improving nighttime sleep quality. - Excessive daytime sleepiness (associated with narcolepsy): enhances wakefulness and functional alertness during the day. - Cataplexy episodes: specifically diminishes sudden loss of muscle tone triggered by strong emotions.

Adverse reactions may occur with sodium oxybate therapy. Patients should be aware of both common and serious potential events.

Common Side Effects: - Nausea - Headache - Dizziness - Vomiting - Insomnia - Anxiety

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Seizures - Allergic reactions (rash, angioedema) - Confusion or hallucinations - Abuse potential and dependence

Sodium oxybate requires careful monitoring and specific safety measures.

- Dose titration: adjust under direct medical supervision to minimize adverse effects. - Alcohol avoidance: do not consume alcohol while taking this medication. - Driving and operating machinery: avoid until individual response is known. - Renal impairment: use with caution and consider dose adjustment. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at below 25°C: keep in the original pack, protect from moisture.

Sodium oxybate can interact with several other medicines, requiring attention to avoid harmful outcomes.

Major Interactions (Avoid): - Alcohol: additive CNS depression. - Other CNS depressants (benzodiazepines, opioids): risk of profound sedation. - MAO inhibitors: potential for severe hypotension. - Illicit GHB: increased toxicity and overdose risk. - Antihistamines with sedating properties: enhanced drowsiness.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: may augment blood pressure lowering. - Antidepressants (SSRIs, SNRIs): monitor for increased sedation. - Antiepileptic drugs: possible alteration of seizure threshold. - Anticholinergic agents: watch for additive cognitive effects. - Caffeine‑containing products: may counteract therapeutic sleep benefits.